UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

The New England journal of medicine, 2019-07, Vol.381 (1), p.13-24

2019

Volltextzugriff (PDF)

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

Journal of clinical oncology, 2009-08, Vol.27 (23), p.3842-3848

2009

Volltextzugriff (PDF)

Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study

International journal of urology, 2021-03, Vol.28 (3), p.280-287

2021

Volltextzugriff (PDF)

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Journal of clinical oncology, 2021-07, Vol.39 (20), p.JCO2003488-2303

2021

Volltextzugriff (PDF)

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

Future oncology (London, England), 2024-03, Vol.20 (10), p.563-578

2024

Volltextzugriff (PDF)

Do Antihistamines Have a Role in Asthma Therapy?

Pharmacotherapy, 2001-03, Vol.21 (3P2), p.28S-33S

Larsen, Julie S.

2001

Volltextzugriff (PDF)

PD34-11 PROSTATE-SPECIFIC ANTIGEN KINETICS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH APALUTAMIDE: RESULTS FROM THE TITAN AND SPARTAN STUDIES

The Journal of urology, 2021-09, Vol.206 (Supplement 3)

2021

Volltextzugriff (PDF)

Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5541-5541

2020

Volltextzugriff (PDF)

Abstract 776: Androgen receptor (AR) and non-AR aberrations associated with outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.776-776

2020

Volltextzugriff (PDF)

Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5535-5535

2020

Volltextzugriff (PDF)

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

The New England journal of medicine, 2023-10, Vol.389 (17), p.1553-1565

2023

Volltextzugriff (PDF)

Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.87-87

2020

Volltextzugriff (PDF)

Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.11-11

2021

Volltextzugriff (PDF)

PD10-11 APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES

The Journal of urology, 2020-04, Vol.203 (Supplement 4)

2020

Volltextzugriff (PDF)

First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5006-5006

2019

Volltextzugriff (PDF)

Evaluation of Conventional Press-and-Breathe Metered-Dose Inhaler Technique in 501 Patients

The Journal of asthma, 1994, Vol.31 (3), p.193-199

1994

Volltextzugriff (PDF)

A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS8601-TPS8601

2015

Volltextzugriff (PDF)

Randomized phase II open-label study of abiraterone acetate (AA) plus low-dose prednisone (P) with or without exemestane (E) in postmenopausal women with ER+ metastatic breast cancer (MBC) progressing after letrozole or anastrozole therapy

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS666-TPS666

2012

Volltextzugriff (PDF)

Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS5097-TPS5097

2013

Volltextzugriff (PDF)

A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS8611-TPS8611

2014

Volltextzugriff (PDF)

Leukotriene-receptor antagonists and 5-lipoxygenase inhibitors in asthma

The Annals of pharmacotherapy, 1993-07, Vol.27 (7-8), p.898-903

1993

Volltextzugriff (PDF)

Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML)

Blood, 2008-11, Vol.112 (11), p.560-560

2008

Volltextzugriff (PDF)

Phase II Study of Low-Dose Decitabine for the Front-Line Treatment of Older Patients with Acute Myeloid Leukemia (AML)

Blood, 2006-11, Vol.108 (11), p.1984-1984

2006

Volltextzugriff (PDF)

Preliminary Results of a Phase II Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Myelodysplastic Syndrome (MDS)

Blood, 2007-11, Vol.110 (11), p.1450-1450

2007

Volltextzugriff (PDF)

1 – 25 von 656

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(597)
Mit Volltextzugriff
(533)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB-FREE-00999 freely available EZB journals
(319)
MEDLINE
(277)
Journals@Ovid
(253)
Connected Ingenta
(248)
Single Journals
(156)
Access via ScienceDirect (Elsevier)
(110)
IngentaConnect Journals
(96)
EZB-NALI5-00465 Elsevier Archive NL
(81)
Access via Wiley Online Library
(78)
Wiley Online Library Full Collection 2018
(57)
SpringerNature Journals
(38)
Access via Oxford University Press
(36)
Access via Taylor & Francis
(36)
Access via Taylor & Francis
(33)
Taylor & Francis Current Content Access
(31)
Nature
(28)
Access via SAGE
(23)
Oxford Journals 2020 Medicine
(22)
Thieme Connect Journals
(22)
JSTOR
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(31)
Journal Of Clinical Oncology
(22)
Seminars In Thrombosis And Hemostasis
(18)
Plos One
(11)
Schizophrenia Research
(9)
Cancer Research
(8)
Nature
(7)
Nature Communications
(7)
Ssrn Electronic Journal
(7)
Vaccine
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

Do Antihistamines Have a Role in Asthma Therapy?

PD34-11 PROSTATE-SPECIFIC ANTIGEN KINETICS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH APALUTAMIDE: RESULTS FROM THE TITAN AND SPARTAN STUDIES

Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies

Abstract 776: Androgen receptor (AR) and non-AR aberrations associated with outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease

Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)

PD10-11 APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES

First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)

Evaluation of Conventional Press-and-Breathe Metered-Dose Inhaler Technique in 501 Patients

A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma

Randomized phase II open-label study of abiraterone acetate (AA) plus low-dose prednisone (P) with or without exemestane (E) in postmenopausal women with ER+ metastatic breast cancer (MBC) progressing after letrozole or anastrozole therapy

Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC)

A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma

Leukotriene-receptor antagonists and 5-lipoxygenase inhibitors in asthma

Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML)

Phase II Study of Low-Dose Decitabine for the Front-Line Treatment of Older Patients with Acute Myeloid Leukemia (AML)

Preliminary Results of a Phase II Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Myelodysplastic Syndrome (MDS)

Suchergebnisse filtern